NewsYour current location: Home -> News

Jiudian have got the production approval of Levocetirizine DI-hydrochloride oral solution

发布者:原料药事业部    发布时间:2018/11/7 9:46:00

Recently, the oral solution of Levocetirizine DI-hydrochloride (H20183089), independently developed by Jiudian Pharmaceutical, was approved by CFDA. We becoming the third company to produce this product on the market in China.

Compared with the similar products in the market, there are no sedative side effects, no cardiac toxicity, and because the dosage is small, the side effects of taking are reduced, and the range of applicable population is enlarged, which provides a safe and effective drug for children.

Previous:Jiudian pharmaceutical's new manufacturing base received the frist GMP certificate
Next:Jiudian pharmaceutical successfully listed